Market News AIOpen the app

CORT stock news · Corcept Therapeutics

Stories about Corcept Therapeutics (CORT) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CORT

Follow Corcept Therapeutics (CORT) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CORT
Free on the App Store and Google Play, or on the web.
  1. Nov 3, 2026, 7:20 PM ET · Market

    Corcept Therapeutics shared its third-quarter results, showing sales of $340.5 million, up 33% from last quarter.

    Good for CORT

    Corcept reported $340.5 million in Q3 sales, up 33% from the prior quarter, and $126.8 million in profit. These results favor the company.

  2. Oct 20, 2026, 6:46 PM ET · Market

    Corcept Therapeutics says the ADA and EASD recommend screening for hypercortisolism in their new diabetes report.

    Good for CORT

    Corcept said diabetes groups recommend screening adults with hard-to-manage type 2 diabetes for excess cortisol. This could help doctors find people for its therapies, a positive sign.

  3. Sep 25, 2026, 1:43 PM ET · Market

    Today, there are big trades happening in 10 health care stocks.

    Neutral

    The article lists a Corcept call sweep tagged bullish. One options trade, without news about the company's business, does not change its outlook.

  4. Sep 23, 2026, 8:35 AM ET · Market

    Corcept Therapeutics says some directors and officers are leaving, while new ones are being hired and paid.

    Neutral

    Corcept filed an 8-K about director and officer changes; no specifics were disclosed, so it does not change our reading of the company.